Impacting Cancer

Nextech Invest, February 2016
Is this email not displaying correctly?
View it in your browser.

Dear Reader, 

In this issue, we share with you our perspective on the US Cancer Moonshot program and highlight some of the progress that our portfolio companies have made. We welcome Prof. Dr. Kai Wucherpfennig from the Dana-Farber Cancer Institute as scientific consultant to Nextech Invest and are pleased to introduce him as a key opinion leader in cancer immunology with an exclusive interview. Our Nextech Insights series continues with the art and science of forming an investor syndicate by Thilo Schroeder, Partner at Nextech Invest.

With kind regards, 
The Nextech Team

Editorial

US Cancer Moonshot is Launched

After the original announcement in October 2015, the US Cancer Moonshot is beginning to take shape. In this article we provide you with an overview of the current status and what the program means to cancer drug development and investing in oncology.

Read the article

Science Perspectives

Kai W. Wucherpfennig, MD PhD, Joins Nextech Invest as Scientific Consultant

Kai Wucherpfennig, MD PhD, is Professor of Microbiology and Immunology and Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute, and Professor of Neurology at Harvard Medical School. We are pleased to announce him as a new scientific consultant to Nextech Invest and give you a brief introduction through an exclusive interview where he talks about his career and the future of cancer immunotherapy.


Read the interview

Nextech Insights

The Art and Science of Forming a Syndicate

 

Read the article.

Thilo Schroeder, PhD, Partner  at Nextech Invest, provides his insight into lessons learned and key considerations of forming a successful investor syndicate for an oncology company.

 

Tracon Pharmaceuticals (NASDAQ:TCON) received orphan drug status for TRC105, a clinical stage antibody, in soft tissue sarcoma after favorable review by the FDA. Furthermore, a phase II trial in glioblastoma with the lead compound, TRC102, has been initiated.

Read the press releases

ImaginAb announced the appointment of Benjamin Chen, PhD, as CEO and Joseph Limber as chairman of the board of directors. In addition, ImaginAb announ-ced the creation of its medical advisory board, composed of leading experts in immuno-oncology.

Read the press release

TetraLogic (NASDAQ:TLOG) announced results of the interim analysis of the phase II clinical study of their lead compound birinapant in combination with azacitidine in myelodysplastic syndro-mes. The drug showed no benefit over azacitidine alone on the primary endpoint.

Read the press release

Blueprint Medicines (NASDAQ:BPMC), has been added to the NASDAQ Biotechnology Index® (NASDAQ:NBI) with effect on December 21, 2015. Joining the biotech industry benchmark.

Read the press release.  

Impressum
Nextech Invest Ltd.
Turnerstrasse 26
8006 Zurich, Switzerland

Web: www.nextechinvest.com
E-Mail: info@nextechinvest.com